1787-23-1

Usage

Uses

Used in Pharmaceutical Research:
4-[4-(Dimethylamino)benzylidene]-2-methyl-1,3-oxazol-5(4H)-one is used as a key building block for the synthesis of potential drug compounds, leveraging its unique structure and reactivity to contribute to the development of new pharmaceuticals.
Used in Cancer Treatment Development:
In the field of oncology, 4-[4-(Dimethylamino)benzylidene]-2-methyl-1,3-oxazol-5(4H)-one is utilized as a component in the research and development of pharmaceuticals aimed at treating various types of cancer. Its incorporation into drug compounds may enhance their efficacy and safety profiles.
Used in Infectious Disease Treatment Development:
4-[4-(Dimethylamino)benzylidene]-2-methyl-1,3-oxazol-5(4H)-one is also used in the development of pharmaceuticals for infectious diseases, where its unique molecular properties may contribute to the creation of effective treatments with fewer side effects.
Used in Neurological Disorder Treatment Development:
In the realm of neurology, 4-[4-(Dimethylamino)benzylidene]-2-methyl-1,3-oxazol-5(4H)-one is employed in the research for potential pharmaceuticals to address neurological disorders. Its structural attributes may offer new avenues for therapeutic intervention in conditions that are currently challenging to treat.
Overall, 4-[4-(Dimethylamino)benzylidene]-2-methyl-1,3-oxazol-5(4H)-one's role in pharmaceutical research is multifaceted, with applications across various medical fields, underscoring its importance in drug discovery and development. Further exploration of its properties could lead to the creation of innovative therapeutic agents with improved efficacy and safety.

Upstream product

• 100-10-7 4-dimethylamino-benzaldehyde 
• 543-24-8 N-acetylglycine 

Downstream Products

• 1384247-61-3 N-benzyl-2-(acetamido)-3-(4-dimethylaminophenyl)acrylamide 
• 1384247-31-7 4-(4-dimethylaminobenzylidene)-1-benzyl-2-methylimidazol-5-one 
• 1384247-69-1 N-methyl-2-(acetamido)-3-(4-dimethylaminophenyl)acrylamide 
• 1373956-82-1 4-(4-(dimethylamino)benzylidene)-2-methyl-1-(pyridin-4-ylmethyl)-1H-imidazol-5(4H)-one 
• 148874-99-1 N-[(2-{4-[1-(4-Dimethylamino-phenyl)-meth-(Z)-ylidene]-2-methyl-5-oxo-4,5-dihydro-imidazol-1-yl}-phenylcarbamoyl)-methyl]-benzamide 
• 140935-45-1 2-(Benzothiazol-2-ylsulfanyl)-N-{4-[1-(4-dimethylamino-phenyl)-meth-(Z)-ylidene]-2-methyl-5-oxo-4,5-dihydro-imidazol-1-yl}-acetamide 
• 1575728-56-1 1-(4-chloro-6-methylpyrimidin-2-yl)-4-(4-(dimethylamino)benzylidene)-2-phenyl-1H-imidazol-5(4H)-one 
• 1575728-38-9 1-(4-chloro-6-methylpyrimidin-2-yl)-4-(4-(dimethylamino)benzylidene)-2-methyl-1H-imidazol-5(4H)-one 
• 1575727-93-3 4-(4-(dimethyl amino) benzylidene)-1-(4-hydroxy-6-methylpyrimidin-2-yl)-2-phenyl-1H-imidazol-5(4H)-one 
• 1575727-70-6 4-(4-(dimethylamino)benzylidene)-1-(4-hydroxy-6-methylpyrimidin-2-yl)-2-methyl-1H-imidazol-5(4H)-one 
• 140935-55-3 2-(Benzooxazol-2-ylsulfanyl)-N-{4-[1-(4-dimethylamino-phenyl)-meth-(Z)-ylidene]-2-methyl-5-oxo-4,5-dihydro-imidazol-1-yl}-acetamide 

Relevant academic research and scientific papers

Fluorescent dye probe for latent fingerprint detection and preparation method and application thereof

The invention relates to a fluorescent dye probe for latent fingerprint detection and a preparation method and application thereof, wherein the core chemical structural formula of the probe is shown I. In-flight R1 The aromatic ring (comprising

Dual-emission fluorescent probe for detecting beta-amyloid protein plaque as well as preparation method and application of dual-emission fluorescent probe

The invention discloses a dual-emission fluorescent probe for detecting beta-amyloid protein plaques as well as a preparation method and application of the dual-emission fluorescent probe. The structure of the fluorescent probe is shown as a formula (I).

Dual-Emission GFP Chromophore-Based Derivative for Imaging and Discriminating Aβ Oligomers and Aggregates

β-Amyloid deposition is one of the main pathological features of Alzheimer’s disease (AD). The development of fluorescent probes targeting specific β-amyloid species has recently become an attractive strategy to achieve the early diagnosis of AD. In this

Synthesis and biological evaluation of imidazoline derivatives as potential CNS and CVS agents

A series of substituted imidazoline derivatives were synthesized and characterized. Compounds were tested in-vivo for their antihypertensive, analgesic, antiaggressive, depressant, antidepressant, and ALD50 activities. The compounds 3a, 3c, 4c, 5a, and 6c showed cardiovascular as well as central nervous system activities and are potential candidate as drug among all fifteen compounds tested. All these compounds have shown better activity for antihypertensive, analgesic, antiaggressive, and depressant-antidepressant, properties than reference compounds clonidine, morphine, diazepam, and imipramine respectively. Most of the compounds have shown ALD50 > 500 mg/kg with maximum in 4a and 5a (>1000 mg/kg).

Synthesis, in-vitroreverse transcriptase inhibitory activity and docking study of some new imidazol-5-one analogs

Non-nucleoside reverse transcriptase inhibitors have a definitive role and most commonly used in treatment of HIV-1 infection. A new series of 4-ethylidene/substituted-benzylidene-1-(4-hydroxy/chloro-6-methylpyrimidin-2-yl) -2-ethyl/phenyl-1H-imidazol-5(4H)-one were designed, synthesized, and evaluated for HIV-1 reverse transcriptase (RT) inhibitory activity. The results of in-vitro HIV-1 RT assay showed that some of the new compounds, such as 4c, 4d, 4e, 5a, and 5e effectively inhibit HIV-1 RT activity. 1-(4-Chloro-6- methylpyrimidin-2-yl)-4-(furan-2-ylmethylene)-2-methyl-1H-imidazol-5(4H)-one (5e) exerted most potent in-vitro HIV-1 RT inhibitory activity, among the group of compounds. Molecular docking studies were carried out to explore the binding affinity of imidazole-5-one analogs in active site of HIV-1 RT enzyme. Springer Science+Business Media 2014.

Facile synthesis of 4-arylidene-5-imidazolinones as synthetic analogs of fluorescent protein chromophore

A facile and effective synthesis for a wide variety of 4-arylidene-5- imidazolinone derivatives was developed. 4-Arylidene-5-oxazolinones were prepared by Erlenmeyer azlactone synthesis from N-acylglycines and arylaldehydes. The ring-opening reactions of the 4-arylidene-5-oxazolinones with primary amines afforded 2-acylamino-3-arylacrylamides in excellent yields. A new dehydrative cyclization of the 2-acylamino-3-arylacrylamides in pyridine under reflux furnished the corresponding 4-arylidene-5-imidazolinones in good yields.

Synthesis, biological activity and docking study of imidazol-5-one as novel non-nucleoside HIV-1 reverse transcriptase inhibitors

A novel series of substituted imidazol-5-ones were designed, synthesized and evaluated for in vitro reverse transcriptase (RT) inhibition activity using reverse transcriptase assay kit (Roche, Colorimetric). It has been observed from in vitro screening that newly synthesized compounds possess RT inhibitory activity. Docking study was performed to study the binding orientation and affinity of synthesized compounds for RT enzyme.

Synthesis of some new 2-methyl-4-(substituted benzylidene) 1-phenyl-1,2,4 triazolo [3,4,-b] 1,3,4 thiadiazole as potential AChE inhibitory agents

4-(1-aminophenyl) -1,2,4 - triazolo [3,4,-b] 1,3,4-thiadiozole (2) was prepared by treatment of 4-(1-aminophenyl)-5-mercapto-4-amino-1,2,4-S-triazole with carbondisulfide and KOH in methanol. This on further reaction with different 2-methyl-4-(substituted

Synthesis of 2-(2-benzothiazoyl/benzoxazoylthio)-N--5-oxo-2-phenyl/methyl-1H-imidazol-1-yl>acetamides as possible anthelmintics

Twenty new 2-(2-benzothiazolyl/benzoxazolylthio)-N--5-oxo-2-phenyl/methyl-1H-imidazol-1-yl>acetamides have been synthesised and tested for their anthelmintic activity against H. nana infection in mice.